Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center and University Hospital of Lausanne experience

BACKGROUND: Uveal melanoma exhibits a high incidence of metastases and no systemic therapy clearly improves outcomes. The anti-CTLA-4 antibody ipilimumab is a standard of care for metastatic melanoma; however, the clinical activity of CTLA-4 inhibition in patients with metastatic uveal melanoma is p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Luke, Jason J., Callahan, Margaret K., Postow, Michael A., Romano, Emanuela, Ramaiya, Nikhil, Bluth, Mark, Giobbie-Hurder, Anita, Lawrence, Donald P., Ibrahim, Nageatte, Ott, Patrick A., Flaherty, Keith T., Sullivan, Ryan J., Harding, James J., D'Angelo, Sandra, Dickson, Mark, Schwartz, Gary K., Chapman, Paul B., Wolchok, Jedd D., Hodi, F. Stephen, Carvajal, Richard D.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3986037/
https://ncbi.nlm.nih.gov/pubmed/23913718
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28282
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados